Litigation Details for Helsinn Healthcare S.A. v. Hospira Inc. (D. Del. 2015)

Helsinn Healthcare S.A. v. Hospira Inc. (D. Del. 2015)

Docket		Date Filed	2015-03-25
Court	District Court, D. Delaware	Date Terminated	2018-09-11
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094
Link to Docket	External link to docket

Details for Helsinn Healthcare S.A. v. Hospira Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-25				External link to document
2015-03-25	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,947,724 B2; 7,947,725 B2; 7,960,424… 11 September 2018 1:15-cv-00264 830 Patent None District Court, D. Delaware	External link to document

Helsinn Healthcare S.A. v. Hospira Inc. Litigation Summary, Case No. 1:15-cv-00264

Last updated: September 29, 2026

Helsinn Healthcare S.A. sued Hospira Inc. in the U.S. District Court for the District of Delaware after Hospira submitted an abbreviated new drug application seeking approval to market generic palonosetron hydrochloride injection, the active ingredient in Helsinn's Aloxi product. The case involved Orange Book-listed patents covering palonosetron formulations and dosing. The litigation was part of a broader patent campaign involving Teva and other generic applicants.

What drug and patents were involved in Helsinn v. Hospira?

The dispute concerned Aloxi, an intravenous palonosetron hydrochloride product used to prevent chemotherapy-induced nausea and vomiting. Helsinn marketed Aloxi in the United States. Hospira's ANDA sought approval for a generic palonosetron injection.

The asserted patent group included patents later examined in related Helsinn litigation involving Teva:

Patent	General subject matter	Relevance
U.S. Patent No. 7,947,724	Palonosetron dosing and pharmaceutical use	Listed for Aloxi-related protection
U.S. Patent No. 8,337,785	Palonosetron formulation and treatment technology	Asserted in the Aloxi patent campaign
U.S. Patent No. 8,598,219	Palonosetron pharmaceutical composition	Central to later validity disputes
U.S. Patent No. 8,609,863	Palonosetron pharmaceutical composition and concentration	Central to later validity disputes
U.S. Patent No. 8,729,094	Palonosetron dosing and treatment regimen	Asserted in related ANDA litigation

The precise patent claims at issue depended on the claims Helsinn selected in response to Hospira's ANDA notice. The case was filed as a Hatch-Waxman action under the statutory framework triggered by a Paragraph IV certification.

When was Helsinn v. Hospira filed?

Helsinn filed the complaint on March 27, 2015, in the District of Delaware. The case was assigned Case No. 1:15-cv-00264 and was handled by Judge Richard G. Andrews.

The lawsuit followed Hospira's notice that its ANDA allegedly challenged Helsinn's listed patents. Filing the action within the statutory period triggered the FDA's 30-month stay of approval for Hospira's ANDA, subject to earlier termination or other statutory events.

Event	Date or period
Complaint filed	March 27, 2015
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00264-RGA
Plaintiff	Helsinn Healthcare S.A.
Defendant	Hospira Inc.
Product	Generic palonosetron hydrochloride injection
Regulatory pathway	ANDA with Paragraph IV challenge
Presiding judge	Richard G. Andrews

What was Hospira's Paragraph IV challenge?

Hospira's ANDA certification placed Helsinn's patents directly in dispute. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The litigation therefore presented two principal questions:

1. Whether Hospira's proposed palonosetron product would infringe the asserted claims.
2. Whether the claims were valid and enforceable in view of the prior art and statutory requirements.

The patents were vulnerable to conventional Hatch-Waxman defenses, including anticipation, obviousness, lack of written description, lack of enablement, and possible patent-term or listing issues. Palonosetron formulation patents also raised technical questions concerning concentration, excipients, stability, dosage, and the relationship between formulation composition and therapeutic use.

What patent claims did Helsinn assert against Hospira?

The asserted claims were directed to palonosetron pharmaceutical products and associated treatment methods rather than to a new chemical entity in the ordinary small-molecule sense. The patent estate sought to protect commercial attributes of Aloxi, including:

• The palonosetron active ingredient in an injectable formulation.
• Concentration and dosage parameters.
• Pharmaceutical compositions suitable for intravenous administration.
• Treatment of chemotherapy-induced nausea and vomiting.
• Use of palonosetron in specified patient or chemotherapy settings.
• Formulation characteristics intended to support product stability and administration.

Helsinn's broader litigation strategy relied on layering composition, formulation, and method-of-use rights. That approach is common where the core compound patent has expired or provides limited remaining term. A generic applicant may avoid one claim category while remaining exposed to another, particularly if the ANDA product must use the same active ingredient and route of administration.

What were the main technical and legal issues?

The litigation involved the standard technical issues associated with an ANDA for an injectable formulation.

Formulation infringement

The composition claims required comparison between the claimed palonosetron formulation and Hospira's proposed product. Relevant issues included the concentration of palonosetron, excipient selection, pH, formulation stability, and whether the ANDA product met each limitation either literally or under the doctrine of equivalents.

Method-of-use infringement

Method claims raised a separate question: whether Hospira's labeling would induce infringement by directing use of palonosetron for the patented antiemetic indications. In ANDA cases, proposed labeling can create substantial exposure even when the generic manufacturer does not directly administer the drug.

Validity

Hospira's defenses likely focused on whether the claimed formulation or dosing regimen would have been obvious to a skilled person based on earlier palonosetron formulations, other 5-HT3 antagonists, clinical data, and routine optimization of injectable products.

The related Helsinn v. Teva litigation later placed particular attention on the on-sale bar under pre-America Invents Act law. That issue concerned whether an earlier commercial transaction involving the claimed invention constituted prior art even when the transaction did not publicly disclose all technical details. The Federal Circuit initially addressed the issue, and the Supreme Court later held that an inventor's sale or offer for sale can qualify as prior art under the America Invents Act even when the sale does not publicly disclose the invention's details. (Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 2019)

The Supreme Court decision arose from the Teva case, not directly from the Hospira docket, but it affected the legal context surrounding Helsinn's related palonosetron patents.

What was the litigation status and outcome?

The Hospira case was resolved and closed rather than proceeding to a publicly reported trial judgment comparable to the later Federal Circuit proceedings in Helsinn v. Teva. Public docket materials identify a dismissal resolving the dispute, but the publicly available court record does not establish a complete set of commercial settlement terms.

The public record does not support treating the Hospira case as a merits ruling that definitively upheld every Helsinn patent against Hospira. The case should be classified as a resolved ANDA action with limited public disclosure of the business terms.

Issue	Publicly supportable assessment
Case status	Closed
Disposition	Resolved by dismissal
Public merits judgment against Hospira	Not established as the final disposition
Public settlement terms	Limited or unavailable in the docket materials
Generic launch date	Not established by the public dismissal record
Effect on related Helsinn cases	No automatic preclusive effect on Teva or other defendants

Did Hospira launch generic Aloxi?

The public dismissal record alone does not establish that Hospira launched its generic palonosetron product, the date of any launch, or whether Hospira received a license for an agreed entry date.

This distinction matters commercially. A Hatch-Waxman case can end through settlement with several possible outcomes:

• A license allowing entry on a negotiated date.
• A license conditioned on regulatory approval or manufacturing readiness.
• A no-launch or delayed-launch agreement.
• A transfer, divestiture, or abandonment of the ANDA.
• A commercial resolution involving an authorized generic.
• Dismissal following a separate agreement whose terms are not filed publicly.

The case docket should not be used by itself to infer an immediate generic launch or a finding that Hospira's product was noninfringing.

What was the relationship to Helsinn v. Teva?

Helsinn's case against Teva involved many of the same Aloxi-related patent rights and generated the principal appellate decisions on the patent estate. The Federal Circuit held that certain asserted claims were infringed and addressed invalidity arguments concerning the on-sale bar. The Supreme Court later affirmed the legal rule that a commercial sale may trigger the statutory on-sale bar even when the sale does not publicly disclose the invention.

The two matters should be analyzed separately:

Issue	Hospira case	Teva case
Case number	1:15-cv-00264	Separate District of New Jersey and appellate proceedings
Defendant	Hospira Inc.	Teva Pharmaceuticals USA Inc.
Product	Generic palonosetron injection	Generic palonosetron injection
Public final merits record	Limited	Substantial appellate record
Supreme Court review	No	Yes
On-sale-bar precedent	Indirectly relevant	Directly litigated

The Teva decisions provide important context for claim validity and patent interpretation, but they do not automatically determine Hospira's liability. Infringement depends on the specific ANDA formulation, proposed labeling, asserted claims, and litigation stipulations in the Hospira matter.

What was the commercial significance of the case?

The case concerned a product with limited formulation flexibility. Palonosetron injection is a regulated sterile drug product, and a generic entrant must satisfy both patent and FDA requirements. Even after resolving patent risk, Hospira would have faced manufacturing, comparability, stability, sterile-fill, quality-system, and supply-chain requirements.

The commercial exposure for Helsinn depended on the timing and number of approved generic entrants. A single injectable generic can pressure price and hospital contracting, while multiple entrants can accelerate erosion. The impact also depends on whether the generic product is therapeutically substitutable under state pharmacy law and whether purchasers use institutional contracts rather than retail pharmacy substitution.

How strong was the Helsinn Aloxi patent estate?

The estate was stronger than a single compound patent because it combined several claim types. That structure increased the number of potential infringement theories but also created multiple validity attack points.

Strengths

• Multiple patents covered composition, formulation, dosing, and use.
• Intravenous palonosetron products were technically constrained by the reference product.
• Method-of-use claims could create labeling-based exposure.
• Related litigation produced favorable decisions on several claims.

Weaknesses

• Formulation claims were exposed to obviousness challenges based on routine pharmaceutical development.
• Method claims depended on the scope of the proposed generic label.
• The on-sale-bar issue created material risk for certain patents.
• Patent expiration limited the period during which litigation could delay competition.
• A dismissal without a public merits judgment reduced the value of the Hospira docket as precedent.

What is the current regulatory and Orange Book relevance?

Aloxi-related patents were listed in the FDA Orange Book and formed the basis for Helsinn's ANDA litigation. Orange Book listings can trigger Paragraph IV litigation, but they do not guarantee that every listed patent will block approval or commercial launch. FDA approval timing remains separate from patent liability.

The relevant regulatory questions are:

• Whether Hospira's ANDA received final approval.
• Whether any 30-month stay expired or was terminated.
• Whether a patent settlement imposed a launch restriction.
• Whether the approved label retained the patented use.
• Whether the product was approved as therapeutically equivalent to Aloxi.
• Whether any pediatric exclusivity or patent-term adjustment affected the blocking period.

The court docket does not, by itself, provide a complete regulatory history. FDA approval and Orange Book records must be read together with the dismissal order and any publicly filed settlement documents.

Key Takeaways

• Helsinn sued Hospira in March 2015 over an ANDA for generic palonosetron hydrochloride injection.
• The dispute involved Aloxi-related formulation, composition, dosing, and method-of-use patents.
• The action was a Paragraph IV Hatch-Waxman case in the District of Delaware before Judge Richard G. Andrews.
• The case closed through dismissal rather than a broadly reported merits judgment against Hospira.
• Public docket materials do not establish the full settlement terms or a generic launch date.
• Related Helsinn v. Teva litigation produced the principal appellate rulings concerning the patent estate and the on-sale bar.
• The Hospira matter remains relevant to generic-entry analysis, but it should not be treated as a published merits precedent or proof of Hospira's launch rights.

FAQs About Helsinn Healthcare S.A. v. Hospira Inc.

What was Hospira's generic product in the case?

Hospira's ANDA concerned generic palonosetron hydrochloride injection, a product intended to compete with Helsinn's Aloxi intravenous product.

Was Hospira found to infringe Helsinn's Aloxi patents?

The public disposition does not establish a final merits judgment finding Hospira liable for infringement. The case was resolved and dismissed.

Did Helsinn and Hospira sign a public settlement?

The docket reflects resolution of the case, but the publicly available record does not disclose a complete set of commercial settlement terms.

Did the Supreme Court decide Helsinn v. Hospira?

No. The Supreme Court decided Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., which involved related Aloxi patents and the statutory on-sale bar.

Does the Hospira dismissal prove that generic Aloxi entered the market?

No. A dismissal does not establish whether Hospira launched, received a license, abandoned its ANDA, or agreed to a delayed entry date.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. Helsinn Healthcare S.A. v. Hospira, Inc., No. 1:15-cv-00264-RGA, U.S. District Court for the District of Delaware.

3. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017).

4. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019).

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.